肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

AACR 2014：肺癌新药MK-3475作用与肿瘤中PD-L1蛋白浓度有关

2014-04-13 MedSci MedSci原创

AACR肺癌生物标志物PD-L1
关注

应用正在研究中的免疫检测点抑制剂MK-3475治疗的非小细胞肺癌患者中，那些肿瘤中PD-L1蛋白浓度较高的患者的预后更好，该I期临床研究结果报告在2014年4月5-9日举行的AACR年会上。该试验的初始数据报道于今年的早些时候，数据显示MK-3475治疗的耐受性较好，可以使以前治疗过的非小细胞肺癌患者达到持久而客观的缓解，尤其是那些在治疗前PD-L1的浓度就很高的肿瘤的患者。最近的结果扩展了这些数

应用正在研究中的免疫检测点抑制剂MK-3475治疗的非小细胞肺癌患者中，那些肿瘤中PD-L1蛋白浓度较高的患者的预后更好，该I期临床研究结果报告在2014年4月5-9日举行的AACR年会上。

该试验的初始数据报道于今年的早些时候，数据显示MK-3475治疗的耐受性较好，可以使以前治疗过的非小细胞肺癌患者达到持久而客观的缓解，尤其是那些在治疗前PD-L1的浓度就很高的肿瘤的患者。

最近的结果扩展了这些数据，结果显示在开始治疗6个月时，41%的PD-L1浓度较高的患者疾病未发生进展，而仅有17%的PD-L1浓度较低的患者疾病未发生进展。相似的，72%的PD-L1浓度较高的患者现在仍活着，而仅有53%的PD-L1浓度较低的患者现在存活。

波士顿哈佛大学医学院医学副教授，同时也是Dana-Farber癌症研究所的胸部肿瘤学家的Leena Gandhi教授表示，以前治疗过的非小细胞肺癌患者的治疗前景很差，因此williamhill asia 迫切需要新的治疗方案。williamhill asia 发现，肿瘤PD-L1表达较高的患者的缓解相当持久，这是非常令人兴奋的。

Gandhi解释道，称作T细胞的免疫细胞天生就能够杀伤癌细胞，但是一些癌细胞能够通过激活T细胞抑制器来阻止T细胞攻击他们。其中一种方式就是通过肿瘤表面的一种叫做PD-L1的蛋白，这种蛋白能够使PD-1粘附在T细胞表面。MK-3475通过抑制T细胞表面的PD-1，并阻止它粘附在PD-L1上，从而破坏肿瘤的这种抑制器。

Gandhi和他的同事们纳入了多个非小细胞肺癌的患者进行I期临床试验。他们分析了治疗前肿瘤PD-L1的浓度的数据，146位患者的信息完整。他们通过免疫组化测量发现，PD-L1的浓度超过50%可以作为PD-L1阳性和阴性肿瘤的最佳临界值。41位治疗前PD-L1浓度较高的患者中，缓解率为37%，而治疗前PD-L1浓度较低的患者中，缓解率仅为11%。

这些数据提示，肿瘤PD-L1浓度高是判断非小细胞肺癌患者应用MK-3475治疗受益的生物标志物。williamhill asia 将把PD-L1表达分析的全组的数据公布出来。这些结果（从一开始的38位患者）扩展了williamhill asia 的发现，一个正在进行的随机试验将前瞻性评估PD-L1表达在判断MK3475和多西他赛治疗中的作用。

版权声明：
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于williamhill asia 医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章，或“williamhill asia 号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系，williamhill asia 将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=306683, encodeId=7dc530668393, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 17 15:02:06 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254873, encodeId=eb1312548e346, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400301, encodeId=90041400301d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544383, encodeId=280c15443833a, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551948, encodeId=f2241551948ba, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8976, encodeId=e48c89e657, content=抗 PD-1类药物，在肿瘤中大显身手呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:58:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8974, encodeId=217b89e464, content=MK-3475是什么机制？抑制PD-L1表达？, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8975, encodeId=5aef89e5b6, content=查到了，果然是Anti-PD-1 Antibody MK-3475, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2018-04-17 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=306683, encodeId=7dc530668393, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 17 15:02:06 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254873, encodeId=eb1312548e346, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400301, encodeId=90041400301d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544383, encodeId=280c15443833a, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551948, encodeId=f2241551948ba, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8976, encodeId=e48c89e657, content=抗 PD-1类药物，在肿瘤中大显身手呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:58:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8974, encodeId=217b89e464, content=MK-3475是什么机制？抑制PD-L1表达？, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8975, encodeId=5aef89e5b6, content=查到了，果然是Anti-PD-1 Antibody MK-3475, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-15 smartjoy

    #PD-L1#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=306683, encodeId=7dc530668393, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 17 15:02:06 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254873, encodeId=eb1312548e346, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400301, encodeId=90041400301d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544383, encodeId=280c15443833a, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551948, encodeId=f2241551948ba, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8976, encodeId=e48c89e657, content=抗 PD-1类药物，在肿瘤中大显身手呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:58:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8974, encodeId=217b89e464, content=MK-3475是什么机制？抑制PD-L1表达？, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8975, encodeId=5aef89e5b6, content=查到了，果然是Anti-PD-1 Antibody MK-3475, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-15 10518094zz

    #ACR#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=306683, encodeId=7dc530668393, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 17 15:02:06 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254873, encodeId=eb1312548e346, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400301, encodeId=90041400301d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544383, encodeId=280c15443833a, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551948, encodeId=f2241551948ba, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8976, encodeId=e48c89e657, content=抗 PD-1类药物，在肿瘤中大显身手呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:58:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8974, encodeId=217b89e464, content=MK-3475是什么机制？抑制PD-L1表达？, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8975, encodeId=5aef89e5b6, content=查到了，果然是Anti-PD-1 Antibody MK-3475, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-15 12498974m55暂无昵称

    #浓度#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=306683, encodeId=7dc530668393, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 17 15:02:06 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254873, encodeId=eb1312548e346, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400301, encodeId=90041400301d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544383, encodeId=280c15443833a, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551948, encodeId=f2241551948ba, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8976, encodeId=e48c89e657, content=抗 PD-1类药物，在肿瘤中大显身手呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:58:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8974, encodeId=217b89e464, content=MK-3475是什么机制？抑制PD-L1表达？, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8975, encodeId=5aef89e5b6, content=查到了，果然是Anti-PD-1 Antibody MK-3475, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-15 Luyuxie_14

    #AACR#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=306683, encodeId=7dc530668393, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 17 15:02:06 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254873, encodeId=eb1312548e346, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400301, encodeId=90041400301d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544383, encodeId=280c15443833a, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551948, encodeId=f2241551948ba, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8976, encodeId=e48c89e657, content=抗 PD-1类药物，在肿瘤中大显身手呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:58:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8974, encodeId=217b89e464, content=MK-3475是什么机制？抑制PD-L1表达？, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8975, encodeId=5aef89e5b6, content=查到了，果然是Anti-PD-1 Antibody MK-3475, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-13 anit

    抗 PD-1类药物，在肿瘤中大显身手呀

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=306683, encodeId=7dc530668393, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 17 15:02:06 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254873, encodeId=eb1312548e346, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400301, encodeId=90041400301d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544383, encodeId=280c15443833a, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551948, encodeId=f2241551948ba, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8976, encodeId=e48c89e657, content=抗 PD-1类药物，在肿瘤中大显身手呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:58:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8974, encodeId=217b89e464, content=MK-3475是什么机制？抑制PD-L1表达？, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8975, encodeId=5aef89e5b6, content=查到了，果然是Anti-PD-1 Antibody MK-3475, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-13 anit

    MK-3475是什么机制？抑制PD-L1表达？

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=306683, encodeId=7dc530668393, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Apr 17 15:02:06 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254873, encodeId=eb1312548e346, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400301, encodeId=90041400301d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544383, encodeId=280c15443833a, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551948, encodeId=f2241551948ba, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Tue Apr 15 12:34:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8976, encodeId=e48c89e657, content=抗 PD-1类药物，在肿瘤中大显身手呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:58:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8974, encodeId=217b89e464, content=MK-3475是什么机制？抑制PD-L1表达？, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8975, encodeId=5aef89e5b6, content=查到了，果然是Anti-PD-1 Antibody MK-3475, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anit, createdTime=Sun Apr 13 22:57:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-13 anit

    查到了，果然是Anti-PD-1 Antibody MK-3475

    0

相关威廉亚洲官网

AACR2013：他汀类药物可显著降低乳腺癌死亡率

一项大型数据库研究显示，在乳腺癌诊断前后使用他汀类药物可使乳腺癌死亡风险降低66%。在美国癌症研究协会(AACR)2013年会上该研究的作者Teemu Murtola医生报道说即使在控制年龄、肿瘤分期、以及形态学特征和初治方案等因素后发现风险减少的趋势依然不变。 约翰霍普金斯大学的流行病学家Teemu J. Murtola医生及其同事指出，“在他汀类药物使用者人群中，williamhill asia 观察到乳腺癌死亡风险存在